A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
← catalyst calendarNCT05120349 · readout in 348 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
390actual
Sites
139
Countries
Argentina, Brazil, Canada +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-02-21 | actual | When the study began enrolling |
| Primary completion | 2027-08-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-11-01 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Osimertinib — also filed as AZD9291; TAGRISSO
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFDisease-Free Survival (DFS) in high-risk stratum
measured From date of randomisation up to approximately 10 years
Publications
- PMID 40311309 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed